Herantis Pharma Oyj (HRTIS.HE)
EUR 1.66
(0.91%)
EUR 1.66
(0.91%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -5.46 Million EUR | -1005.37% |
| 2022 | -49.46 Million EUR | -6602.12% |
| 2021 | 760.82 Thousand EUR | 114.82% |
| 2020 | -5.13 Million EUR | -528.15% |
| 2019 | 1.19 Million EUR | -78.84% |
| 2018 | 5.66 Million EUR | -12.54% |
| 2017 | 6.47 Million EUR | -11.71% |
| 2016 | 7.33 Million EUR | 2.15% |
| 2015 | 7.18 Million EUR | 75.08% |
| 2014 | 4.1 Million EUR | 123.88% |
| 2013 | 1.83 Million EUR | 9.76% |
| 2012 | 1.66 Million EUR | 66.73% |
| 2011 | 1 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -1.95 Million EUR | 64.17% |
| 2024 Q2 | -1.95 Million EUR | 0.0% |
| 2023 Q2 | 615 Thousand EUR | 0.0% |
| 2023 FY | -5.46 Million EUR | 88.95% |
| 2023 Q3 | -5.46 Million EUR | -989.14% |
| 2023 Q4 | -5.46 Million EUR | 0.0% |
| 2023 Q1 | 615 Thousand EUR | 224.32% |
| 2022 Q4 | -49.46 Million EUR | -9899.98% |
| 2022 Q3 | -494.69 Thousand EUR | 78.35% |
| 2022 FY | -49.46 Million EUR | -6602.12% |
| 2022 Q1 | -2.28 Million EUR | -400.33% |
| 2022 Q2 | -2.28 Million EUR | 0.0% |
| 2021 Q2 | 324 Thousand EUR | 0.0% |
| 2021 Q4 | 760.82 Thousand EUR | 0.0% |
| 2021 Q3 | 760.82 Thousand EUR | 134.82% |
| 2021 FY | 760.82 Thousand EUR | 114.82% |
| 2021 Q1 | 324 Thousand EUR | 106.31% |
| 2020 Q2 | -1.89 Million EUR | -104.52% |
| 2020 FY | -5.13 Million EUR | -528.15% |
| 2020 Q1 | -928.01 Thousand EUR | -177.4% |
| 2020 Q4 | -5.13 Million EUR | 0.0% |
| 2020 Q3 | -5.13 Million EUR | -170.46% |
| 2019 Q1 | 2.15 Million EUR | -62.06% |
| 2019 Q2 | 2.15 Million EUR | 0.0% |
| 2019 FY | 1.19 Million EUR | -78.84% |
| 2019 Q4 | 1.19 Million EUR | 0.0% |
| 2019 Q3 | 1.19 Million EUR | -44.24% |
| 2018 Q3 | 5.66 Million EUR | -5.17% |
| 2018 Q2 | 5.97 Million EUR | 0.0% |
| 2018 Q1 | 5.97 Million EUR | -7.77% |
| 2018 FY | 5.66 Million EUR | -12.54% |
| 2018 Q4 | 5.66 Million EUR | 0.0% |
| 2017 Q1 | 8.02 Million EUR | 9.3% |
| 2017 FY | 6.47 Million EUR | -11.71% |
| 2017 Q2 | 8.02 Million EUR | 0.0% |
| 2017 Q4 | 6.47 Million EUR | 0.0% |
| 2017 Q3 | 6.47 Million EUR | -19.22% |
| 2016 Q4 | 7.33 Million EUR | 0.0% |
| 2016 Q1 | 7.09 Million EUR | -1.23% |
| 2016 Q2 | 7.09 Million EUR | 0.0% |
| 2016 FY | 7.33 Million EUR | 2.15% |
| 2016 Q3 | 7.33 Million EUR | 3.42% |
| 2015 Q1 | 5.27 Million EUR | 28.45% |
| 2015 FY | 7.18 Million EUR | 75.08% |
| 2015 Q3 | 7.18 Million EUR | 36.3% |
| 2015 Q4 | 7.18 Million EUR | 0.0% |
| 2015 Q2 | 5.27 Million EUR | 0.0% |
| 2014 Q2 | -7.97 Million EUR | -645.51% |
| 2014 Q3 | 4.1 Million EUR | 151.45% |
| 2014 FY | 4.1 Million EUR | 123.88% |
| 2014 Q4 | 4.1 Million EUR | 0.0% |
| 2014 Q1 | 1.46 Million EUR | -20.23% |
| 2013 Q3 | 1.83 Million EUR | 0.0% |
| 2013 Q4 | 1.83 Million EUR | 0.0% |
| 2013 FY | 1.83 Million EUR | 9.76% |
| 2013 Q1 | 1.69 Million EUR | 0.0% |
| 2012 FY | 1.66 Million EUR | 66.73% |
| 2011 FY | 1 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Biohit Oyj | -2.3 Million EUR | -137.748% |
| Nanoform Finland Oyj | -7.97 Million EUR | 31.426% |